References
- Bjorkholm M, Ohm L, Eloranta S, . Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008. J Clin Oncol 2011;29:2514–2520.
- de Lavallade H, Apperley JF, Khorashad JS, . Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol 2008;26:3358–3363.
- Gromicho M, Dinis J, Magalhães M, . Development of imatinib and dasatinib resistance: dynamics of expression of drug transporters ABCB1, ABCC1, ABCG2, MVP, and SLC22A1. Leuk Lymphoma 2011;52:1980–1990.
- le Coutre P, Tassi E, Varella-Garcia M, . Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood 2000;95:1758–1766.
- Sherbenou DW, Hantschel O, Kaupe I, . BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib. Blood 2010;116:3278–3285.
- O’Hare T, Shakespeare WC, Zhu X, . AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 2009;16:401–412.
- Cortes J, Talpaz M, Bixby D, . A phase I trial of oral ponatininb (AP24534) in patients with refractory chroninc myeloid leukemia (CML) and other hematologic malignancies: emerging safety and clinical response findings. Blood 2010;16(Suppl. 1): Abstract 210.
- Tanaka R, Squires MS, Kimura S, . Activity of the multitargeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL-positive leukemic cells. Blood 2010;116:2089–2095.
- Chan WW, Wise SC, Kaufman MD, . Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036. Cancer Cell 2011;19:556–568.
- Zhang J, Adrián FJ, Jahnke W, . Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. Nature 2010; 463:501–506.
- Zhang H, Trachootham D, Lu W, . Effective killing of Gleevec-resistant CML cells with T315I mutation by a natural compound PEITC through redox-mediated mechanism. Leukemia 2008;22:1191–1199.
- Pillai RN, Chen LS, Ayres ML, . Multifaceted actions of 8-amino-adenosine kill BCR-ABL positive cells. Leuk Lymphoma 2012;53:2024–2032.